ClinicalTrials.gg
WithdrawnNCT04213274Updated Nov 15, 2024

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

A Phase 2 interventional study of 80 mg RPH-104 and Placebo in Schnitzler Syndrome and Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder), sponsored by R-Pharm Overseas, Inc.. Withdrawn at 4 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-15.

Sponsored by R-Pharm Overseas, Inc. (part of R-Pharm) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
due to the decision of company Top management

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Paraproteinemias with a site in United States — 6 open to participants now, 12 under way, 2 of them phase 3. Paraproteinemias · United States.

Enrollment
31st of 32
0 · median 47
Started
2023
with 1 other
Phase 2
11 of 39
none open now
Registered
32nd of 39
by date

Among the 39 studies in Paraproteinemias with a site in United States, this one is the 31st largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2023, is one of 11 in phase 2, and was the 32nd registered.

Paraproteinemias

69 studies on the registry are indexed under Paraproteinemias; 22 are open to participants now.

Browse Paraproteinemias studies →

Open to participants now

6 of the 39 studies in Paraproteinemias with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Paraproteinemias studies recruiting now, 7 (54%) set no upper age limit and 3 (23%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Paraproteinemias with a site in United States, or all of them as a file.
02

Study summary

The primary goal of the study is to assess the efficacy and safety of RPH-104 in subjects with Schnitzler Syndrome using Schnitzler Disease Activity Score (SDAS), which includes the Physician's Global Assessment (PGA) and the local laboratory C-reactive protein (CRP) result

Read the detailed description

The study will include a screening period (up to 28 days), a double blind, placebo controlled treatment period (14 days), followed by an 8 week safety follow up period after the second dose of study drug.

Subjects with an established diagnosis of Schnitzler Syndrome (SchS) will participate in a Screening period of up to 28 days after signing an informed consent form (ICF). Subjects will be advised to schedule the Day 0 visit with the study staff as soon as the symptoms of SchS flare occur during the Screening period.

If the subject does not meet the inclusion/exclusion criteria at the site visit during the screening period, other screening visits are allowed within this period until the subject meets the study criteria.

A total of 14 subjects will be randomly assigned to 1 of 2 treatment groups (in a 1:1 ratio) to receive a double blind, single subcutaneous (SC) injection of study drug (80 mg RPH-104 or matching placebo) on Day 0. On Day 14, subjects will receive a second dose of randomized treatment as well as an additional dose of 80 mg RPH-104 or placebo based on response to treatment, such that responders (SDAS = 0) will receive a dose of placebo, and non responders defined as no response (no change in SDAS) or partial responders (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) will receive an 80 mg RPH 104 dose. (Schnitzler Disease Activity Score includes the PGA score and C-reactive protein (CRP) result: If the PGA and CRP grades are not of the same severity, the higher severity level of either PGA or CRP will be used to determine the SDAS)

The study will be stopped after Data and Safety Monitoring Board (DSMB) review if:

  1. Death is reported in 2 subjects assigned to the RPH 104 treatment arm or after receiving RPH 104 on Day 14 (i.e., non responder to the Day 0 study drug dose).
  2. Two subjects assigned to the RPH 104 treatment arm or after receiving RPH 104 on Day 14 (ie, non responder to the Day 0 study drug dose) report liver function test abnormalities which meet Hy's Law criteria (ie, increased ALT and/or AST 3 fold or greater from upper limit of normal (ULN) combined with jaundice or weakness or hypochondrial pain/severity or increased Total Bilirubin (TBil) level 2 fold or greater from ULN, [not explained by any other causative factors like virus]).

The severity of SchS symptoms will be assessed daily from Day 0 through Day 28 using the PR SchS Scale, at clinic visits on Day 0, Day 14, and Day 28 using the Patient Global Impression of Severity (PGIS), at clinic visits on Day 14 and Day 28 using the Patient Global Impression of Change (PGIC), and at each clinic visit using the PGA, CRP, SAA, and SDAS. Subjects will be followed through Day 70 for safety (A Data Safety Monitoring Board (DSMB) will periodically review and evaluate the accumulated study data for subject safety).

03

Conditions studied

  • Schnitzler Syndrome
  • Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)

Browse trials for

Keywords

  • neutrophilic urticarial dermatosis
  • autoinflammatory syndrome
  • monoclonal gammopathy
  • neutrophilic dermatosis
  • interleukin-1
  • Schnitzler syndrome
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Able to read, understand and willing to sign the ICF and abide with study procedures. The ICF must be signed and dated prior to performing any Screening assessment.
    1. Confirmed diagnosis of SchS based on diagnostic criteria adapted by Lipsker as an urticarial skin rash (chronic), monoclonal IgM component (ie, IgM \< 10 g/L), or IgG (variant type), and at least of 2 of the following:

      • Fever (intermittent)
      • Arthralgia or arthritis
      • Bone pain
      • Lymphadenopathy
      • Hepato and/or splenomegaly
      • Elevated erythrocyte sedimentation rate (ESR) and/or leukocytosis
      • Bone abnormalities (on radiological or histological investigation)
    1. Subjects with symptomatic SchS (as defined by SDAS with a score of 2 or more with a CRP [local laboratory] levels > 10 mg/L) on the day of randomization.
    1. Willing, committed, and able to return for all clinic visits and complete all study related procedures, including willingness to have SC injections administered by a qualified person.
    1. Males, female partners of sexually active male subjects, and women of (WOCBP) (defined as all female subjects with physiological potential to conceive) must agree to use highly effective methods throughout the study starting from Screening (signing ) through at least 8 weeks after the final dose of study drug.

Highly effective contraceptive method is defined as follows:

  1. Complete abstinence: if it corresponds to the preferred and conventional lifestyle of the female subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation method) and interrupted coitus are not considered acceptable contraceptive methods.
  2. Sterilization: surgical bilateral ovariectomy (with/without hysterectomy) or tubal ligation at least 6 weeks prior to the study therapy initiation. In case of ovariectomy only the female reproductive status should be verified by further hormonal test.
  3. Sterilization of male partner with documented absence of sperm in ejaculate post vasectomy for at least 6 months (vasectomized male partner should be the only partner of the participating female subject).
  4. Combination of 2 of the following methods (i + ii, i + iii, or ii + iii):

i. Oral, injectable, or implanted hormonal contraceptives; in case of oral contraceptives the female subjects should administer the same product for at least 3 months prior to the study therapy.

ii. Intrauterine device or contraceptive system.

iii. Barrier methods: condom or occlusive cap (diaphragm or cervical cap/vaginal fornix cap) with spermicidal foam/gel/film/cream/vaginal suppository.

    1. WOCBP must have negative pregnancy tests at Screening (serum chorionic gonadotropin test), and all subsequent visits (urine).

Exclusion criteria

Exclusion Criteria:

    1. to the study drug (RPH 104) and/or its components/ and/or the products of the same chemical class.
    1. Concurrent/on going treatment with anakinra (Kineret) or recent treatment within 5 days prior to Day 0.
    1. Concurrent/on going treatment with other biologics or recent treatment within 4 weeks or 5 × t½ prior to Day 0, whichever is longer.
    1. Concurrent/on going treatment with agents (eg, cyclosporine, methotrexate, dapsone, colchicine, or others) within 4 weeks or 5 × t½ prior to Day 0, whichever is longer.
    1. Concurrent/on going treatment with high doses of systemic (> 0.2 mg/kg/day prednisolone equivalent). Intra articular, peri articular, intravenous, or intramuscular corticosteroid injections within 4 weeks prior to the Day 0 visit.
    1. Administration of live (attenuated) vaccine within 3 months prior to Day 0 and necessity of administration for 3 months after Day 70.
  • 7.

    1. History of active tuberculosis (TB), evidence of active or latent M. tuberculosis infection as defined by local guidelines/local medical practice at Screening.
    2. Positive QuantiFERON Gold Plus (TB) test at Screening.
    3. Chest X ray findings confirming pulmonary TB at Screening.
    1. Active bacterial, fungal, or viral infection(s) within 4 weeks prior to Day 0.
    1. A history of persistent chronic bacterial, fungal, or viral infection(s) requiring treatment with parenteral antibiotics, parenteral antivirals, or parenteral antifungals within 4 weeks prior to Day 0.
    1. Opportunistic infections and/or Kaposi's sarcoma at the time of Screening.
    1. Any other relevant concomitant diseases (infectious, cardiovascular, nervous, endocrine, urinary, gastrointestinal, hepatic disorders, coagulation disorders, and other /autoinflammatory diseases, etc) or conditions which, according to the investigator's judgment, may affect the subject's participation or well being in the study and/or distort assessment of the study results.
    1. History of within 5 years prior to screening other than successfully treated non , basal, or squamous cell carcinoma of the skin and/or in situ cancer.
    1. Evidence of lymphoproliferative diseases (except SchS associated monoclonal gammopathy).
    1. Presence of any of the following laboratory abnormalities at screening visit: white blood cell count (WBC) \< 3000/µL; count \< 75,000/µL; (ALT) or aspartate aminotransferase (AST) > 3.0 × (ULN), TBil > 2 × ULN unless due to Gilbert's syndrome.
    1. Severe renal failure: creatinine clearance \< 30 mL/min.
    1. Women who are either pregnant or lactating.
    1. Subjects for whom there is concern about compliance with the protocol procedures.
    1. Psychiatric disorders which, according to the investigator's judgment, may affect the subject participation in the study and his/her ability to follow the protocol procedures.
    1. History of organ transplantation or transplantation is anticipated during the study.
    1. Concomitant participation in other clinical studies at the start of Screening or administration of any unauthorized () products less than 4 weeks or 5 × t½ periods (whichever is longer) before Day 0 (treatment initiation).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo - placebo

    Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to treatment (SDAS = 0) one more dose of placebo

    Drug: Placebo

  • Other
    Placebo - 80 mg RPH-104

    Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) subcutaneous single injection of 80 mg RPH-104

    Biological: 80 mg RPH-104 · Drug: Placebo

  • Experimental
    80 mg RPH-104 - 80 mg RPH-104

    Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to the treatment (SDAS = 0) one subcutaneous injection of placebo

    Biological: 80 mg RPH-104 · Drug: Placebo

  • Experimental
    80 mg RPH-104 - 160 mg RPH-104

    Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) one more subcutaneous injection of 80 mg RPH-104

    Biological: 80 mg RPH-104

Interventions

  • Biological80 mg RPH-104

    solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

  • DrugPlacebo

    Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with complete response (Schnitzler Disease Activity Score (SDAS = 0)) to therapy on Day 14 in the RPH-104 group as compared to the placebo group

    • Proportion of subjects with complete response (SDAS = 0) to therapy on Day 14 in the RPH 104 treated group as compared to the placebo group based on SDAS using the PGA and the local laboratory CRP result

    Time frame: Day 14

Secondary outcomes

  1. Change from baseline to Day 14 in subject-reported symptom severity of SchS: Patient-reported Severity of Schnitzler Syndrome Scale (PR-SchS Scale)

    Change from baseline to Day 14 in subject-reported symptom severity of SchS using the Patient-reported Severity of Schnitzler Syndrome Scale (PR-SchS Scale). The PR-SchS Scale includes 5 features that are the most common and important SchS symptoms. These include rash, fever, tiredness, joint pain, and bone/muscle pain.

    Time frame: Baseline and Day 14

  2. Proportion of subjects with normalized serum amyloid A (SAA) and C-reactive protein (CRP) at Days 14 and 28

    Proportion of subjects with normalized SAA (\< 10 mg/L) and CRP (≤ 10 mg/L) at Days 14 and 28

    Time frame: Day 14 and Day 28

  3. Change from baseline to Day 14 and Day 28 in CRP and SAA

    Change from baseline to Day 14 and Day 28 in C-reactive protein and serum amyloid A

    Time frame: Baseline, Day 28 and Day 14

  4. Proportion of subjects with complete response (SDAS = 0) to therapy on Day 28 by treatment sequence based on SDAS using the Physician's Global Assessment (PGA) and the CRP result

    Proportion of subjects with complete response (SDAS = 0) to therapy on Day 28 by treatment sequence (placebo - placebo, placebo - 80 mg RPH 104, 80 mg RPH 104 80 mg RPH 104, and 80 mg RPH 104 - 160 mg RPH 104) based on SDAS using the PGA and the CRP result.

    Time frame: Baseline and Day 28

  5. Proportion of subjects with partial response by treatment sequence on Days 14 and 28

    Proportion of subjects with partial response (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) by treatment sequence (placebo - placebo, placebo 80 mg RPH 104, 80 mg RPH 104 80 mg RPH 104, and 80 mg RPH 104 160 mg RPH 104) on Days 14 and 28

    Time frame: Baseline, Day 14 and Day 28

Other outcomes

  1. Change from baseline to Day 28 in subject reported symptom severity of SchS using the PR SchS Scale

    Change from baseline to Day 28 in subject reported symptom severity of SchS using the PR SchS Scale

    Time frame: Baseline, Day 14 and Day 28

  2. Change from baseline to Day 14 and Day 28 in the Short Form-36 Version 2 Health Survey®

    Change from baseline to Day 14 and Day 28 in the Short Form-36 Version 2 Health Survey® (SF 36v2 scale scores).It should be completed by the subject to assess of their quality of life over the preceding week.The SF 36v2 is a 36 item, patient reported survey of patient health. It consists of 8 health domains, including: Vitality,Physical functioning,Bodily pain, General health perceptions, Physical role functioning, Emotional role functioning, Social role functioning, Mental health.The SF 36v2 also produces 2 summary scores: the physical component summary (PCS) and mental component summary (MCS) scores

    Time frame: Baseline, Day 14 and Day 28

  3. Change from baseline to Day 14 and Day 28 in PGA total score

    Change from baseline to Day 14 and Day 28 in PGA (Physician's Global Assessment) total score. 5 key symptoms of SchS (urticarial rash, fatigue, fever, myalgia, and arthralgia/bone pain) will be evaluated with a PGA score. Each symptom to be graded on a 4-point Likert scale where 0 = no, 1 = mild, 2 = moderate, and 3 = severe disease activity. The total PGA score to be ranged between 0 and 15.

    Time frame: Baseline, Day 14 and Day 28

  4. Change from baseline to Day 14 and Day 28 in PGIS scores

    Change from baseline to Day 14 and Day 28 in PGIS scores (Patient Global Impression of Severity score: The PGIS asks subjects to describe the severity of their symptoms right now.Subjects are asked: "Please choose the response below that best describes the severity of your Schnitzler Syndrome symptoms today". Subjects rate their symptoms on a 5-point scale as "None", "Mild", "Moderate", "Severe", or "Very Severe")

    Time frame: Baseline, Day 14 and Day 28

  5. Proportion of subjects who are "Much Better" or "A Little Better" in PGIC scores at Day 14 and Day 28

    Proportion of subjects who are "Much Better" or "A Little Better" in PGIC scores at Day 14 and Day 28. (PGIC is a 5-point scale, where the subjects should rate the overall change in their symptoms by comparing the severity of their symptoms right now with the severity of their symptoms before they began study treatment. Subjects are asked: "Please choose the response below that best describes the overall change in your Schnitzler Syndrome symptoms since you started taking the study medication". Subjects report their change in symptoms as "Much better","A Little Better", "No Change", "A Little Worse", or "Much worse")

    Time frame: Day 14 and Day 28

  6. Change from baseline to Day 14 and Day 28 in IgG levels

    Change from baseline to Day 14 and Day 28 in immunoglobulin G (IgG) levels

    Time frame: Baseline, Day 14 and Day 28

  7. Change from baseline to Day 14 and Day 28 in IgM levels

    Change from baseline to Day 14 and Day 28 in immunoglobulin M (IgM) levels

    Time frame: Baseline, Day 14 and Day 28

  8. Change from baseline to Day 14 and Day 28 in IgA levels

    Change from baseline to Day 14 and Day 28 in Immunoglobulin A (IgA) levels

    Time frame: Baseline, Day 14 and Day 28

  9. Change from baseline to Day 14 and Day 28 in Kappa protein levels

    Change from baseline to Day 14 and Day 28 in Kappa protein levels

    Time frame: Baseline, Day 14 and Day 28

  10. Change from baseline to Day 14 and Day 28 in Lambda protein levels

    Change from baseline to Day 14 and Day 28 in Lambda protein levels

    Time frame: Baseline, Day 14 and Day 28

  11. Change from baseline to Day 14 and Day 28 in Paraprotein levels

    Change from baseline to Day 14 and Day 28 in Paraprotein levels

    Time frame: Baseline, Day 14 and Day 28

  12. Change from baseline to Day 14 and Day 28 in Binding and neutralizing antidrug antibodies levels

    Change from baseline to Day 14 and Day 28 in Binding and neutralizing antidrug antibodies levels

    Time frame: Baseline, Day 14 and Day 28

  13. Estimated half-life (t½) of RPH 104

    Estimated t½ of RPH 104

    Time frame: Baseline, Day 14, Day 28, Day 42, Day 70

  14. Change from baseline to Day 14 and Day 28 in IL-1β, IL-1α, IL-1RA, and IL-6 levels

    Change from baseline to Day 14 and Day 28 in IL-1β, IL-1α, IL-1 receptor antagonist (IL-1RA), and IL-6 levels

    Time frame: Baseline, Day 14 and Day 28

  15. Viral testing at Screening

    Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) presence will be assessed

    Time frame: Screening

  16. QuantiFERON Gold Plus (TB) test at Screening

    evidence of no active or latent M. tuberculosis infection as defined by local guidelines/local medical practice

    Time frame: Screening

  17. Pregnancy test for all WOCBP (women of childbearing potential)

    serum chorionic gonadotropin test will be performed at screening and urine tests will be done at Baseline, Day 14, Day 28, Day 42, and Day 70

    Time frame: Screening, Baseline, Day 14, Day 28, Day 42, and Day 70

  18. Change in CRP (C-reactive protein) test results from screening to Day 28

    CRP will be performed at both a local laboratory and the central laboratory. The local laboratory CRP test is to be processed on the same day the clinical assessments occur. Dosing cannot occur until these results are available on Day 0 and Day 14 to ensure eligibility and response to treatment.

    Time frame: Screening, Baseline, Day 14, Day 28

  19. Change in monoclonal proteins levels from baseline to Day 70

    IgG, IgM, IgA, kappa, lambda, and paraprotein levels will be assessed

    Time frame: Baseline, Day 14, Day 28, Day 42, and Day 70

  20. Change in SAA (serum amyloid A) test results from Screening to Day 70

    Serum levels of SAA have been found to be elevated in SchS, and systemic AA amyloidosis as a consequence of chronic inflammation has been reported in SchS.The SAA analysis will be performed at the central laboratory

    Time frame: Screening, Baseline, Day 14, Day 28, Day 42, and Day 70

07

Study locations

4 sites
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Oregon Health & Science University
    Portland, Oregon 97239-3098, United States
  • Penn State Health Hersey Medical Center
    Hershey, Pennsylvania 17033, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2023; primary completion for Aug 2023, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2019
First posted
Dec 30, 2019
StartEst.
May 2023
Primary completionEst.
Aug 2023
CompletionEst.
Jan 2024
Last update
Nov 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04213274
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Dec 30, 2019
Start date
May 2023 (estimated)
Primary completion
Aug 2023 (estimated)
Completion
Jan 2024 (estimated)
Last update
Nov 15, 2024

Study contacts

Yan Lavrovsky
study director · R-Pharm Overseas, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goflikicept

Start the discussion